Shares of Ipca Laboratories declined by 2.11% to Rs 1,342.30 in Monday's session. The stock is a constituent of the Nifty Midcap 150 index.
Financial Performance:
Ipca Laboratories' consolidated financial performance shows the following trends:
Quarterly Results:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,092.63 Crore | Rs 2,354.90 Crore | Rs 2,245.37 Crore | Rs 2,246.69 Crore | Rs 2,308.85 Crore |
| Net Profit | Rs 198.98 Crore | Rs 245.44 Crore | Rs 277.33 Crore | Rs 65.78 Crore | Rs 234.42 Crore |
| EPS | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 |
The revenue for Ipca Laboratories has seen a fluctuating trend over the last five quarters, with a recent increase to Rs 2,308.85 Crore in June 2025. Net profit also varied, with a significant drop in March 2025, followed by a recovery in June 2025.
Annual Results:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 5,419.99 Crore | Rs 5,829.79 Crore | Rs 6,244.32 Crore | Rs 7,705.04 Crore | Rs 8,939.59 Crore |
| Net Profit | Rs 1,148.84 Crore | Rs 910.95 Crore | Rs 491.93 Crore | Rs 529.21 Crore | Rs 787.53 Crore |
| EPS | 45.01 | 34.85 | 18.58 | 25.82 | 35.14 |
| BVPS | 371.79 | 219.51 | 233.16 | 304.57 | 273.88 |
| ROE | 24.24 | 16.09 | 8.06 | 8.64 | 10.61 |
| Debt to Equity | 0.05 | 0.14 | 0.25 | 0.22 | 0.19 |
The annual results show a consistent increase in revenue from 2021 to 2025. Although net profit declined between 2021 and 2023, it has since recovered. The debt-to-equity ratio has remained relatively stable.
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 1,321 Crore | Rs 944 Crore | Rs 805 Crore | Rs 856 Crore | Rs 1,090 Crore |
| Investing Activities | Rs -869 Crore | Rs -1,291 Crore | Rs -725 Crore | Rs -855 Crore | Rs -520 Crore |
| Financing Activities | Rs -282 Crore | Rs -552 Crore | Rs 507 Crore | Rs 426 Crore | Rs -305 Crore |
| Others | Rs 0 Crore | Rs 76 Crore | Rs 0 Crore | Rs 4 Crore | Rs 0 Crore |
| Net Cash Flow | Rs 168 Crore | Rs -823 Crore | Rs 588 Crore | Rs 431 Crore | Rs 263 Crore |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore |
| Reserves & Surplus | Rs 6,923 Crore | Rs 6,306 Crore | Rs 5,816 Crore | Rs 5,466 Crore | Rs 4,676 Crore |
| Current Liabilities | Rs 2,386 Crore | Rs 2,355 Crore | Rs 1,805 Crore | Rs 1,465 Crore | Rs 1,160 Crore |
| Other Liabilities | Rs 2,425 Crore | Rs 2,413 Crore | Rs 978 Crore | Rs 681 Crore | Rs 206 Crore |
| Total Liabilities | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Fixed Assets | Rs 4,798 Crore | Rs 4,805 Crore | Rs 2,853 Crore | Rs 2,669 Crore | Rs 2,260 Crore |
| Current Assets | Rs 6,268 Crore | Rs 5,538 Crore | Rs 5,189 Crore | Rs 4,457 Crore | Rs 3,436 Crore |
| Other Assets | Rs 694 Crore | Rs 756 Crore | Rs 583 Crore | Rs 511 Crore | Rs 370 Crore |
| Total Assets | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Contingent Liabilities | Rs 613 Crore | Rs 303 Crore | Rs 2,125 Crore | Rs 274 Crore | Rs 369 Crore |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 45.01 | 34.85 | 18.58 | 25.82 | 35.14 |
| Diluted Eps (Rs.) | 45.01 | 34.85 | 18.58 | 21.57 | 29.08 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 371.79 | 219.51 | 233.16 | 304.57 | 273.88 |
| Dividend/Share (Rs.) | 8.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Face Value | 2 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 29.65 | 23.59 | 16.85 | 18.76 | 20.34 |
| Operating Margin (%) | 25.79 | 19.61 | 12.66 | 14.12 | 15.89 |
| Net Profit Margin (%) | 21.19 | 15.62 | 7.87 | 6.86 | 8.80 |
| Return on Networth / Equity (%) | 24.24 | 16.09 | 8.06 | 8.64 | 10.61 |
| ROCE (%) | 28.48 | 18.52 | 11.59 | 12.44 | 15.15 |
| Return On Assets (%) | 18.78 | 11.57 | 5.46 | 4.93 | 6.27 |
| Current Ratio (X) | 2.96 | 3.04 | 2.87 | 2.35 | 2.63 |
| Quick Ratio (X) | 1.59 | 1.77 | 1.91 | 1.30 | 1.55 |
| Debt to Equity (x) | 0.05 | 0.14 | 0.25 | 0.22 | 0.19 |
| Interest Coverage Ratios (X) | 177.79 | 178.91 | 23.11 | 10.46 | 21.42 |
| Asset Turnover Ratio (%) | 0.91 | 0.80 | 0.77 | 0.78 | 0.78 |
| Inventory Turnover Ratio (X) | 1.10 | 0.96 | 0.95 | 1.05 | 3.55 |
| 3 Yr CAGR Sales (%) | 28.99 | 24.30 | 15.90 | 19.23 | 23.83 |
| 3 Yr CAGR Net Profit (%) | 117.14 | 43.23 | -10.30 | -32.13 | -7.02 |
| P/E (x) | 21.15 | 30.58 | 43.61 | 47.92 | 42.74 |
| P/B (x) | 5.13 | 4.90 | 3.52 | 4.96 | 5.48 |
| EV/EBITDA (x) | 14.96 | 19.73 | 19.23 | 23.45 | 22.26 |
| P/S (x) | 4.45 | 4.62 | 3.29 | 4.08 | 4.26 |
Ipca Laboratories announced a final dividend of Rs 2.00 per share (200%) on May 29, 2025, with an effective date of August 05, 2025. Additionally, the company had a stock split on January 10, 2022, where the old face value of Rs 2 was split into a new face value of Rs 1. A bonus issue was announced on October 27, 2004, with a bonus ratio of 1:1 and an ex-bonus date of January 28, 2005.
Ipca Laboratories' shares were trading at Rs 1,342.30, a decrease of 2.11% in Monday's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
